text

Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion

FrenchhealthcaregroupSanofihasagreedtobuyU.S.haemophiliaspecialistBioverativfor$11.6billion,inadealwhichitsaidwouldboostearningsandstrengthenitspresenceintreatm